Detection of methylated ABL1 promoter in Philadelphia-negative myeloproliferative disorders

Blood Cells, Molecules, and Diseases

Volumn 30, Issue 1, 2003, Pages 100-106

  Aviram, Adina ^a   Witenberg, Bruria ^a   Shaklai, Mati ^a   Blickstein, Dorit ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

ABL1 promoter; BCR ABL; Essential thrombocythemia; Idiopathic myelofibrosis; Methylation; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

BCR ABL PROTEIN; BISULFITE; GENOMIC DNA;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; GENE EXPRESSION; GENE IDENTIFICATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; MYELOFIBROSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION MAPPING; THROMBOCYTHEMIA;

EID: 0037232676     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00015-9     Document Type: Article

References (29)

1. Fialkow P.J., Faguet G.B., Jacobson R.J., Raidya K., Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in multipotent stem cell. Blood. 58:1981;916-919.
2. Groffen J., Stephenson J.R., Heisterkamp N., De Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region of bcr on chromosome 22. Cell. 36:1984;93-99.
3. Melo J.V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88:1996;2375-2384.
4. Morris C.M., Fitzgerald P.H., Holding P.E., Archer S.A., Rosman I., Beard M.E. Essential thrombocythemia and the Philadelphia chromosome. Br. J. Haematol. 70:1988;13-19.
5. Stoll D.B., Peterson P., Exten R., Laszlo J., Pisciotta A.V., Ellis J.T., White P., Vaidya K., Bozdech M., Murphy S. Clinical presentation and natural history of patients with essential thrombocythemia and the philadelphia chromosome. Am. J. Hematol. 27:1988;77-83.
6. Martiat P., Ifrah N., Rassool F., Morgan G., Giles F., Gow J., Goldman J.M. Molecular analysis of Philadelphia positive essential thrombocythemia. Leukemia. 3:1989;563-565.
7. Michiels J.J., Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Sem. Thromb. Hemost. 23:1997;339-347.
8. Damaj G., Delabesse E., Le Bihan C., Asnafi V., Rachid M., Lefrere F., Radford-Weiss I., Macintyre E., Hermine O., Varet B. Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br. J. Haematol. 116:2002;812-816.
9. Wen S.T., Jackson R.K., Van Etter R.A. The cytostatic function of c-ABL is controlled by multiple nuclear localization signals and requires p53 and Rb suppressor gene products. EMBO J. 15:1995;1583-1595.
10. Guo X.Y.D., Fontana J., Kufe D., Deisseroth A. Antagonistic effects of ABL and BCR-ABL proteins on proliferation and response to genotoxic stress in normal and leukemic myeloid cells. Leukemia Lymphoma. 30:1998;225-235.
11. Ben-Yehuda D., Krichevsky S., Rachmilewitz E.A., Avraham A., Palumbo G.A., Frassoni F., Sahar D., Rosenbaum H., Paltiel O., Zion M., Ben-Neriah Y. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 90:1997;4918-4923.
12. Asimakopoulos F.A., Shteper P.J., Krichevsky S., Fibach E., Polliack A., Rachmilewitz E.A., Ben-Neriah Y., Ben-Yehuda D. Abl1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 94:1999;1-11.
13. Litz C.E., Etzell J. Aberrant DNA methylation of genomic regions translocated in myeloid malignancies. Leukemia Lymphoma. 30:1998;1-9.
14. Blickstein D., Aviram A., Luboshitz J., Prokocimer M., Stark P., Bairey O., Sulkes J., Shaklai M. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients clinical presentation. Blood. 90:1997;2768-2771.
15. Aviram A., Blickstein D., Stark P., Luboshitz J., Bairey O., Prokocimer M., Shaklai M. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytemia patients. Leukemia Lymphoma. 33:1999;77-82.
16. Murphy S., Hand H., Rosenthal D., Laszlo J. Essential thrombocythemia an interim report from the Polycythemia Vera Study Group. Sem. Hematol. 23:1986;177-182.
17. Berlin M.I. Diagnosis and classification of the polycythemias. Semin. Hematol. 12:1975;339-351.
18. Laszlo J. Myeloproliferative disorders (MPD) myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD and hemorrrhagic thrombocythemia. Semin. Hematol. 12:1975;409-432.
19. Seabright M. A rapid banding technique for human chromosomes. Lancet. 2:1971;971.
20. ISCN In: D.G. Harnden, H.P. Klinger (Eds.), An international system for human cytogenetic nomenclature, Published in collaboration with Cytogenet. Cell Genet., Karger, Basel, Switzerland, 1985.
21. Melo J.V., Yan X.H., Diamond J., Lin F., Cross N.C.P., Goldman J.M. Reverse transcriptase/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts the risk in misinterpreting negative results. Leukemia. 10:1996;1217-1221.
22. Singer-Sam J., Grant M., LeBon J.M., Okuyama K., Chapman V., Monk M., Riggs A.D. Use of HpaII polymerase chain reaction assay to study DNA methylation in Pgk-1 CpG island of mouse embryos at the time of X-chromosome inactivation. Mol. Cell Biol. 10:1990;4987-4989.
23. Heller P., Komblihtt L.I., Cuello M.T., Larripa I., Najfeld V., Molinas F.C. BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance. Blood. 98:2001;1990.
24. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., Rojas J., Bourdon A., Bonner P.L., Wang L., Christmas S.E., Travers P.J., Creaser C.S., Rees R.C., Madrigal J.A. Direct evidence that leukemic cells present HLA- associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 98:2001;2887-2893.
25. Goldman J.M. Tyrosine-kinase inhibition in treatment of chronic myeloid leukemia. Lancet. 355:2000;1031-1032.
26. Sun B., Jiang G., Zaydan M.A.A., La Russa V.F., Safah H., Ehrlich M. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors. Cancer Res. 61:2001;6931-6937.
27. Ramchandani S., Bhattacharya S.K., Cervoni N., Szyf M. DNA methylation is a reversible biological signal. Proc. Natl. Acad. Sci. USA. 96:1999;6107-6112.
28. Bhattacharya S.K., Ramchandani S., Cervoni N., Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 397:1999;579-583.
29. Fajkusova I., Fajkus J., Polackova K., Fulnecek J., Dvorakova D., Krahulcova E. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173. Blood Cells Mol. Dis. 26:2000;193-204.